Seven patients (4 men and 3 women, ranging in age from 27 to 64 years) with pigmented paravenous retinochoroidal atrophy, a rare disorder of unknown origin, were studied. The mean follow-up time was 18.5 months. Fundus examinations were performed, and color fundus photographs were taken. In addition to fluorescein angiography, visual field examinations, color vision and electroretinographic tests were performed. All 7 patients were asymptomatic, with visual acuities ranging from 3/10 to 10/10. Both fundi showed patches of retinochoroidal atrophy and pigmentation along the retinal veins in all patients. Fluorescein angiography showed hyperfluorescence due to the pigment epithelial atrophy together with hypofluorescence corresponding to bone spicule pigment clumping. Visual field tests showed scotomas corresponding with areas of atrophy along the retinal veins. The electroretinography showed reduced responses in 2 cases. Color vision was normal in all cases. The patients had no history of trauma or a previous inflammatory process. Serology for syphilis, Toxoplasma and cytomegalovirus as well as a skin test for tuberculosis were negative. When the patients were seen at the end of the follow-up period, no variation of the findings was noted. Although the fundus abnormalities can be mild or severe, retinal function tests indicated that this is a geographic and not a generalized disorder.

Limaye SR, Mahmood MA: Retinal microangiopathy in pigmented paravenous chorioretinal atrophy. Br J Ophthalmol 1987;71:757–761.
Noble KG, Carr RE: Pigmented paravenous chorioretinal atrophy. Am J Ophthalmol 1983;96:338–344.
Traboulsi EI, Maumenee HI: Hereditary pigmented paravenous chorioretinal atrophy. Arch Ophthalmol 1986;104:1636–1640.
Traversi C, Tosi GM, Caporossi A: Unilateral retinitis pigmentosa in a woman and pigmented paravenous chorioretinal atrophy in her daughter and son. Eye 2000;14:395–397.
Noble KG: Hereditary pigmented paravenous chorioretinal atrophy. Am J Ophthalmol 1989;108:365–369.
Johansen J, Lund-Andersen C, Autzen T: Pigmented paravenous chorioretinal atrophy. Acta Ophthalmol 1988;66:474–477.
Batıoğlu F, Atmaca LS, Atilla H, Arslanpence A: Inflammatory pigmented paravenous retinochoroidal atrophy. Eye 2002;16:81–84.
Murray AT, Kirkby GR: Pigmented paravenous retinochoroidal atrophy: A literature review supported by a unique case and insight. Eye 2000;14:711–716.
Yamaguchi K, Hara S, Tanifuji Y, Tamai M: Inflammatory pigmented paravenous retinochoroidal atrophy. Br J Ophthalmol 1989;73:463–467.
Pearlman JT, Heckenlively JR, Bastek JV: Progressive nature of pigmented paravenous retinochoroidal atrophy. Am J Ophthalmol 1978;85:215–217.
Lessel MR, Thaler A, Heilig P: ERG and EOG in progressive paravenous retinochoroidal atrophy. Doc Ophthalmol 1986;62:25–29.
Small KW, Anderson WB Jr: Pigmented paravenous retinochoroidal atrophy: Discordant expression in monozygotic twins. Arch Ophthalmol 1991;109:1408–1410.
Gass JDM: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. St Louis, Mosby, 1997, p 379.
Chen MS, Yang CH, Huang JS: Bilateral macula coloboma and pigmented paravenous retinochoroidal atrophy. Br J Ophthalmol 1992;76:250–251.
Young WO, Small KW: Pigmented paravenous retinochoroidal atrophy (PPRCA) with optic disc drusen. Ophthalmic Paediatr Genet 1993;14:23–27.
Chi H-H: Retinal choroiditis radiata. Am J Ophthalmol 1948;31:1485.
Foxman SG, Heckenlively JR, Sinclair SH: Rubeola retinopathy and pigmented paravenous retinochoroidal atrophy. Am J Ophthalmol 1985;99:605–606.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.